Soluble IL-2R Levels at Baseline Predict the Development of Severe Respiratory Failure and Mortality in COVID-19 Patients.
biomarker
coronavirus disease-19
soluble interleukin-2 receptor
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
10 04 2022
10 04 2022
Historique:
received:
13
03
2022
revised:
02
04
2022
accepted:
08
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
27
4
2022
Statut:
epublish
Résumé
Risk stratification of coronavirus disease-19 (COVID-19) patients by simple markers is critical to guide treatment. We studied the predictive value of soluble interleukin-2 receptor (sIL-2R) for the early identification of patients at risk of developing severe clinical outcomes. sIL-2R levels were measured in 197 patients (60.9% males; median age 61 years; moderate disease,
Identifiants
pubmed: 35458517
pii: v14040787
doi: 10.3390/v14040787
pmc: PMC9025750
pii:
doi:
Substances chimiques
Biomarkers
0
Receptors, Interleukin-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Front Cell Infect Microbiol. 2021 Sep 03;11:651484
pubmed: 34540715
Cytokine. 2021 Apr;140:155438
pubmed: 33493861
N Engl J Med. 2020 Dec 3;383(23):2255-2273
pubmed: 33264547
Elife. 2021 Mar 08;10:
pubmed: 33682678
Biomarkers. 2008 Feb;13(1):1-26
pubmed: 17906988
J Immunol. 2002 Oct 15;169(8):4288-97
pubmed: 12370360
J Innate Immun. 2022;14(3):218-228
pubmed: 34852352
J Clin Oncol. 1987 Aug;5(8):1262-74
pubmed: 3114436
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Br J Cancer. 1995 Aug;72(2):452-5
pubmed: 7640231
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Eur J Intern Med. 2021 Jun;88:52-62
pubmed: 33820686
Clin Immunol Immunopathol. 1989 Mar;50(3):321-32
pubmed: 2783895
Gut. 1993 May;34(5):658-64
pubmed: 8504967
Emerg Microbes Infect. 2020 Dec;9(1):727-732
pubmed: 32196410
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Immunobiology. 2021 Nov;226(6):152136
pubmed: 34628288
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
J Med Virol. 2020 Nov;92(11):2409-2411
pubmed: 32516845
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Lancet Respir Med. 2021 Jun;9(6):622-642
pubmed: 33965003
Nat Med. 2021 Oct;27(10):1752-1760
pubmed: 34480127
iScience. 2021 Jan 22;24(1):101896
pubmed: 33319166
Int J Infect Dis. 2021 Apr;105:522-524
pubmed: 33711520
Front Immunol. 2021 Jan 29;12:626235
pubmed: 33584733
J Clin Med. 2021 Sep 18;10(18):
pubmed: 34575353
Cell Rep Med. 2022 Feb 25;3(3):100560
pubmed: 35474750
JCI Insight. 2021 Jan 11;6(1):
pubmed: 33232303
Immunity. 2020 Jul 14;53(1):19-25
pubmed: 32610079
N Engl J Med. 2020 Dec 17;383(25):2451-2460
pubmed: 32412710
Clin Exp Immunol. 2020 Jul;201(1):76-84
pubmed: 32365221
EBioMedicine. 2021 May;67:103378
pubmed: 34000622
Immunol Lett. 2020 Sep;225:31-32
pubmed: 32569607
Crit Care. 2020 Apr 30;24(1):187
pubmed: 32354367
J Clin Med. 2018 Oct 30;7(11):
pubmed: 30380785
J Immunol. 1985 Nov;135(5):3172-7
pubmed: 3930598
J Intensive Care. 2020 May 24;8:36
pubmed: 32483488
Int J Oral Sci. 2020 Feb 24;12(1):8
pubmed: 32094336
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3
pubmed: 32320677
Cell Mol Immunol. 2020 Aug;17(8):878-880
pubmed: 32587367
Eur J Clin Invest. 1993 Apr;23(4):219-25
pubmed: 7684680